Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Ozempic (semaglutide) belongs to a group of medications called GLP-1 receptor agonists that ... coded according to the dose each pen delivers in milligrams (mg). When you start Ozempic, your ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

The application covers multiple strengths of Semaglutide injection, including: 0.25 mg, 0.5 mg, 1 mg (4 mg/3 mL pre-filled pen) 1.7 mg, 2.4 mg (9.6 mg/3 mL pre-filled pen) The SEC's final approval ...

today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in ...

Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a lower dose of medication.

The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

The semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...